About CStone Pharma
CStone Pharma is a company based in Shanghai (China) founded in 2016.. CStone Pharma has raised $410 million across 3 funding rounds from investors including Pfizer, Taikang Insurance Group and CITIC Capital. The company has 135 employees as of December 31, 2024. CStone Pharma operates in a competitive market with competitors including Brii Biosciences, Affinivax, Neon Therapeutics, Osivax and SpyBiotech, among others.
- Headquarter Shanghai, China
- Employees 135 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Cstone Pharmaceuticals
-
Annual Revenue
$56.85 M (USD)-13.86as on Dec 31, 2024
-
Net Profit
$-12.73 M (USD)75.63as on Dec 31, 2024
-
EBITDA
$-6.36 M (USD)91.83as on Dec 31, 2024
-
Total Equity Funding
$410 M (USD)
in 3 rounds
-
Latest Funding Round
$200 M (USD), Post-IPO
Sep 29, 2020
-
Investors
Pfizer
& 13 more
-
Employee Count
135
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CStone Pharma
CStone Pharma is a publicly listed company on the HKEX with ticker symbol 2616 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Funding Insights of CStone Pharma
CStone Pharma has successfully raised a total of $410M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $200.0M
-
First Round
First Round
(03 Jul 2016)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Post-IPO - CStone Pharma | Valuation |
investors |
|
| May, 2018 | Amount | Series B - CStone Pharma | Valuation | GIC | |
| Jul, 2016 | Amount | Series A - CStone Pharma | Valuation | Oriza Ventures , Boyu Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CStone Pharma
CStone Pharma has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Taikang Insurance Group and CITIC Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sovereign wealth is managed and private equity investments are facilitated.
|
Founded Year | Domain | Location | |
|
Private equity investments are managed by Yunfeng Capital in China.
|
Founded Year | Domain | Location | |
|
Life-Sciences focused early and growth stage VC firm funding companies in China & the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CStone Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CStone Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cstone Pharma Comparisons
Competitors of CStone Pharma
CStone Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Brii Biosciences, Affinivax, Neon Therapeutics, Osivax and SpyBiotech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of biologics to treat hepatitis B infection
|
|
| domain | founded_year | HQ Location |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Tumor-specific neoantigens are identified for personalized cancer vaccine development.
|
|
| domain | founded_year | HQ Location |
Vaccines against mutating pathogens are developed using nanoparticle technology.
|
|
| domain | founded_year | HQ Location |
Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cstone Pharma
Frequently Asked Questions about CStone Pharma
When was CStone Pharma founded?
CStone Pharma was founded in 2016.
Where is CStone Pharma located?
CStone Pharma is headquartered in Shanghai, China.
Is CStone Pharma a funded company?
CStone Pharma is a funded company, having raised a total of $410M across 3 funding rounds to date. The company's 1st funding round was a Series A of $150M, raised on Jul 03, 2016.
How many employees does CStone Pharma have?
As of Dec 31, 2024, the latest employee count at CStone Pharma is 135.
What is the annual revenue of CStone Pharma?
Annual revenue of CStone Pharma is $56.85M as on Dec 31, 2024.
What does CStone Pharma do?
CStone Pharma, a Shanghai-Suzhou startup, is developing and licensing novel drugs with a focus on immuno-oncology along with drugs for cardiovascular diseases, hematology and autoimmune diseases (e.g - rheumatoid arthritis). It has a robust oncology pipeline with eight assets in clinical stages. It is working on various targets including IDHm1, PDL-1, FGFR4, RET, PD-1, etc. The lead molecule, TIBSOVO has got FDA approval.
Who are the top competitors of CStone Pharma?
CStone Pharma's top competitors include Brii Biosciences, Osivax and Affinivax.
Is CStone Pharma publicly traded?
Yes, CStone Pharma is publicly traded on HKEX under the ticker symbol 2616.
Who are CStone Pharma's investors?
CStone Pharma has 14 investors. Key investors include Pfizer, Taikang Insurance Group, CITIC Capital, Arch Venture Partners, and GIC.
What is CStone Pharma's ticker symbol?
The ticker symbol of CStone Pharma is 2616 on HKEX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.